Elosulfase alfa (3) – Vimizim®
Mucopolysaccharidoses (type IVA)
Characteristics
| Start date | 01.05.2025 |
|---|---|
| Resolution | 16.10.2025 |
| INN | Elosulfase alfa |
| Brand name | Vimizim® |
| Pharm. company |
Dossier: BioMarin Deutschland
New distributor: BIOMARIN INTERNATIONAL LIMITED |
| G-BA Procedure ID | D-1200 |
| Therapeutic area | Metabolic diseases Orphan |
| Reason for procedure | not completed: discontinued |
Associated procedures
| Elosulfase alfa (3) | Vimizim® | BioMarin Deutschland | Mucopolysaccharidoses (type IVA) | n.d. | discontinued Orphan | |
| Elosulfase alfa (2) | Vimizim® | BioMarin Deutschland GmbH | Mucopolysaccharidosis (type IVA) | 20–100 | 100% minor additional benefit Orphan | |
| Elosulfase alfa (1) | Vimizim® | BioMarin Deutschland GmbH | Mucopolysaccharidosis (type IVA) |
0
15–95 |
100% minor additional benefit Orphan repealed |
<< List of all resolutions